Wealth Enhancement Advisory Services LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Wealth Enhancement Advisory Services LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 252,954 shares of the biopharmaceutical company’s stock after selling 10,675 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Gilead Sciences were worth $18,529,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Tompkins Financial Corp raised its position in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Private Wealth Management Group LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Sachetta LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $30,000. Finally, Rakuten Securities Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GILD. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Morgan Stanley cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. TD Cowen dropped their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Finally, Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Twelve investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $83.47.

Gilead Sciences Stock Up 0.0 %

Shares of NASDAQ:GILD opened at $68.85 on Friday. The business has a 50-day moving average price of $65.89 and a 200 day moving average price of $72.75. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $85.78 billion, a price-to-earnings ratio of 191.19, a PEG ratio of 2.95 and a beta of 0.20. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the company earned $1.37 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.47%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.16% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.